Abstract: Objective To evaluate the efficacy，side effects and survival of capecitabine plus docetaxel for the first-line treatment of advanced gastric cancer. Methods From January 2010 to July 2012，24 cases of advanced gastric cancer were enrolled to receive capecitabine plus docetaxel regimen. Treatment consisted of 3-week cycles of twicedaily capecitabin 1000mg/m2（on days 1-14）and intravenous docetaxel 75mg／m2 1h, d1 or 35mg／m21h,d1,d8. Each patient received at least 2 cycles. The efficacy was evaluated every two cycles and side effects were evaluated each cycle. Results The efficacy could be evaluated in 24 patients, none of them achieved complete responses，3 showed partial responses，20 had stable disease, and 1 got progressive disease. The response rate was 12.5％ and the disease control rate was 95.8％. The median overall survival was 105 months（95％CI：2.47-18.47months）. Ten patients died from disease progression，and the time to progression of 7 patients was 1.7-15.2months. The main side effects were myelosuppression and hand-foot syndrome， mainly in grade 1-2, and none of them suffered treatment related death. Conclusion Capecitabine plus docetaxel regimen for the first-line treatment of advanced gastric cancer has a definite effect with acceptable toxicity，which is worth further study.